GGrantIndex
← Search

Clinical Trials with Immunotoxins

$860,104ZIAFY2009CANIH

Division Of Basic Sciences - Nci

Investigators

Ira Pastancontact

Linked publications & trials

Paper 34030585Paper 33627164Paper 32077130Paper 31944549Paper 31792036Paper 31628266Paper 30538953Paper 30030507Paper 29143114Paper 28286803Paper 28013405Paper 27863199Paper 26463707Paper 24824231Paper 22355053Paper 22351743Paper 22339074Paper 22149739Paper 22069706Paper 22003067Paper 21998010Paper 21599609Paper 21504287Paper 21037025Paper 20215554Paper 19898744Paper 19814696Paper 19744744Paper 19671873Paper 19414673Paper 18678888Paper 16857795Paper 16681430Paper 16675574Paper 16638849Paper 16428485Paper 16311729Paper 16082249Paper 16061911Paper 15701286Paper 15217923Paper 14734446

Abstract

A multi center phase 1 trial of HA22 in drug resistant hairy cell leukemia is near completion. There have been no dose limiting toxicities and about 40% of patients have achieved a complete remission. A multi center phase 1 trial of HA22 in refectory ALL has opened and eight patients treated. Clinical activity has been observed. This is a collaboration with Dr. Alan Wayne of the Pediatric Oncology Branch. Nine patients with mesothelioma have been treated with SS1P plus chemotherapy. No dose limiting toxicity has occurred and several partial responses observed. Dose escalation is continuing. A phase 2 trial in mesothelioma combining MORAB-009 with chemotherapy has opened. Trail with LMB2 in CTL and ATL are ongoing.

View original record on NIH RePORTER →